Results 201 to 210 of about 88,387 (345)

Dextromethorphan versus Dextrorphan: A Quantitative Comparison of Antitussive Potency following Separate Administration of Metabolite

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract To assess the antitussive effects of dextrorphan (DOR) relative to its parent compound, dextromethorphan (DEX) a double‐blind, randomized, placebo‐controlled crossover study was conducted in 23 healthy volunteers using citric acid cough challenge test after administering placebo, DEX, or DOR.
Saeed Rezaee   +3 more
wiley   +1 more source

Multistage Molecular Simulations, Design, Synthesis, and Anticonvulsant Evaluation of 2-(Isoindolin-2-yl) Esters of Aromatic Amino Acids Targeting GABA<sub>A</sub> Receptors via π-π Stacking. [PDF]

open access: yesInt J Mol Sci
González-Periañez S   +10 more
europepmc   +1 more source

Clinical Evaluation of Drug–Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P‐gp Pathways

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract In addition to antiretroviral therapy (ART), people with HIV often take medications to treat comorbidities. It is therefore important to assess these medications for potential drug‐drug interactions, which may affect the safety and efficacy of ART. Three phase I studies were conducted in adult participants without HIV. The pharmacokinetics (PK)
Priyanka Arora   +4 more
wiley   +1 more source

Involvement of GABA/BDZ receptors in the anticonvulsant effects of dihydrosanguinarine from <i>Bocconia arborea</i> S. Watson. [PDF]

open access: yesHeliyon
González-Gómez JD   +6 more
europepmc   +1 more source

Effect of anticonvulsant therapy on serum 25-hydroxyvitamin D level.

open access: bronze, 1978
Kiyoomi Sumi   +5 more
openalex   +2 more sources

Establishing a Quantitative Framework for Combined Oral Contraceptives: Evaluating the Impact of Drug–Drug Interactions on Exposure and Clinical (Surrogate) Efficacy Endpoints

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract According to the FDA Guidance for Industry on Clinical Drug Interaction (DDI) Studies with Combined Oral Contraceptives (COCs), sponsors are expected to conduct dedicated clinical DDI studies if in vitro findings suggest weak or moderate CYP3A induction, while concomitant use of COCs with strong inducers should be avoided. The guidance further
Dain Chun   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy